SPIRE-2
The Evaluation of Bococizumab (PF-04950615) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2)
- Stadium
- klaar
- Middel
- Bococizumab
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 15 februari 2015
- Last Patient In
- 1 maart 2016
- Last Patient Last Visit
- 23 december 2016
National Lead
dr. A. Mosterd
Cardioloog
Studiedirecteur
